CVS Stock Recent News
CVS LATEST HEADLINES
Healthcare-focused Glenview Capital Management has established a large position in CVS Health and will meet top executives at the struggling healthcare company on Monday to propose ways it can improve its operations, The Wall Street Journal reported on Sunday.
CVS Health (CVS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
NEW YORK, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against CVS Health Corporation (NYSE: CVS) on behalf of long-term stockholders following a class action complaint that was filed against CVS on July 12, 2024 with a Class Period from May 3, 2023 to April 30, 2024. Our investigation concerns whether the board of directors of CVS have breached their fiduciary duties to the company.
In the closing of the recent trading day, CVS Health (CVS) stood at $58.64, denoting a +0.96% change from the preceding trading day.
More than 7,000 workers to hold strike vote this week amid accusations of staff shortages and expensive healthcare
The FTC is suing CVS Health, Cigna, and UnitedHealth Group because of alleged uncompetitive PBM practices. Their PBM units are major revenue sources for all three healthcare companies.
CNBC's Eamon Javers joins 'The Exchange' to report the latest on the FTC's lawsuit against drug middlemen for allegedly inflating insulin prices.
Pharmacy-benefit managers owned by CVS, Cigna and UnitedHealth “artificially inflated” prices for lifesaving medications, regulator alleges.
The US Federal Trade Commission is accusing units of CVS, Cigna, and UnitedHealth of engaging in illegal rebate programs that drove up the price of insulin. Federal Trade Commission Office of Public Affairs Director Douglas Farrar discusses the lawsuit against the pharmacy benefits managers.
The U.S. Federal Trade Commission said on Friday it was suing the country's three largest pharmacy benefit managers, accusing them of abusing their power and rigging the pharmaceutical supply chain to artificially inflate the cost of insulin.